These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 37414267

  • 61. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant.
    Rouce RH, Louis CU, Heslop HE.
    Curr Opin Hematol; 2014 Nov; 21(6):476-81. PubMed ID: 25159713
    [Abstract] [Full Text] [Related]

  • 62. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
    Ali S, AlThubaiti S, Renzi S, Krueger J, Chiang KY, Naqvi A, Schechter T, Punnett A, Ali M.
    Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
    [Abstract] [Full Text] [Related]

  • 63. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.
    Zhu K, Chen J, Chen S.
    Hematology; 2005 Oct; 10(5):365-70. PubMed ID: 16273722
    [Abstract] [Full Text] [Related]

  • 64. Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation.
    Takamatsu H, Araki R, Nishimura R, Yachie A, Espinoza JL, Okumura H, Yoshida T, Kuzushima K, Nakao S.
    J Clin Virol; 2016 Jul; 80():82-6. PubMed ID: 27218416
    [Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73. Epstein-Barr virus-positive mucocutaneous ulcer arising in a post-hematopoietic cell transplant patient followed by polymorphic posttransplant lymphoproliferative disorder and cytomegalovirus colitis.
    Satou A, Kohno A, Fukuyama R, Elsayed AA, Nakamura S.
    Hum Pathol; 2017 Jan; 59():147-151. PubMed ID: 27569297
    [Abstract] [Full Text] [Related]

  • 74. Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation.
    Marjanska A, Styczynski J.
    Expert Opin Biol Ther; 2023 Jan; 23(6):539-552. PubMed ID: 36971380
    [Abstract] [Full Text] [Related]

  • 75. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
    Bonney DK, Htwe EE, Turner A, Kelsey A, Shabani A, Hughes S, Hughes I, Wynn RF.
    Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
    [Abstract] [Full Text] [Related]

  • 76. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, Levitsky V, Remberger M.
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [Abstract] [Full Text] [Related]

  • 77. [Recent advances on diagnosis and therapy of lymphoproliferative disorders after allo-HSCT].
    Gu B, Chen GH, Wu DP.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):538-42. PubMed ID: 24763039
    [Abstract] [Full Text] [Related]

  • 78. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
    [Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
    Raberahona M, Wackenheim C, Germi R, Carré M, Bulabois CE, Thiébaut A, Lupo J, Semenova T, Cahn JY, Morand P, Epaulard O.
    Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.